Clinical Trials Directory

Trials / Completed

CompletedNCT01209754

EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure)

HIV Prevention Agent Pregnancy Exposure Registry: EMBRACE Study

Status
Completed
Phase
Study type
Observational
Enrollment
873 (actual)
Sponsor
Microbicide Trials Network · Network
Sex
All
Age
Healthy volunteers
Accepted

Summary

The Prevention Agent Pregnancy Exposure Registry, also known as EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) is a prospective observational cohort investigation of exposures to study agents under investigation for HIV prevention. The study population will consist of female participants who are identified as becoming pregnant during their participation in a microbicide or PrEP trial, or who have had planned exposures in pregnancy safety studies as well as their babies resulting from these pregnancies. This study will only enroll babies who have not yet reached their 1 year birth date.

Detailed description

The Prevention Agent Pregnancy Exposure Registry, also known as EMBRACE (Evaluation of Maternal and Baby Outcome Registry After Chemoprophylactic Exposure) is a prospective observational cohort study of maternal exposures to investigational HIV prevention agents. Approximately 550 pregnant participants and 400 live infants will be offered enrollment. The study population will consist of current or recent female participants identified as becoming pregnant during microbicide or PrEP trials, or who have had planned exposures in pregnancy safety studies. This study will also include infants resulting from those pregnancies. This protocol will monitor for adverse pregnancy and delivery outcomes, monitor the prevalence of major malformations, evaluate growth parameters of infants during the first year of life, and evaluate the prevalence and persistence of HIV drug resistance mutations in a cohort of infants who were either exposed to active study agents or not exposed to active study agents while in utero.

Conditions

Timeline

Start date
2009-10-01
Primary completion
2020-05-06
Completion
2020-05-06
First posted
2010-09-27
Last updated
2021-06-21

Locations

17 sites across 4 countries: United States, South Africa, Uganda, Zimbabwe

Source: ClinicalTrials.gov record NCT01209754. Inclusion in this directory is not an endorsement.